INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Claims Against Spectrum Pharmaceuticals, Inc. & Advises Inves...
October 29 2015 - 08:53PM
Business Wire
Khang & Khang LLP announces that it is investigating claims
of potential misrepresentations by Spectrum Pharmaceuticals, Inc.
(“Spectrum” or the “Company”) (NASDAQ: SPPI). The investigation
focuses on whether the Company and its officers violated securities
laws by issuing misleading information to investors.
If you purchased shares of Spectrum during the Class Period,
please contact Joon M. Khang, Esquire, of Khang & Khang, 18101
Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by email at joon@khanglaw.com.
There has been no class certification in this case. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
On October 23, 2015, Spectrum announced that it has received a
Complete Response Letter from the U.S. Food and Drug Administration
(FDA) in response to its New Drug Application seeking clearance for
Evomela, indicating that the FDA cannot approve the application in
its present form.
If you wish to learn more about this lawsuit, or if
you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by email at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151029006900/en/
KHANG & KHANG LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2023 to Mar 2024